SLAMF6 antibody (AA 248-331) (FITC)

Catalog No. ABIN7169784

Product Details anti-SLAMF6 Antibody (FITC)

Target: SLAMF6 (SLAM Family Member 6 (SLAMF6))

Binding Specificity: AA 248-331

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SLAMF6 antibody is conjugated to FITC

Application: Please inquire

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human SLAM family member 6 protein (248-331AA)

Isotype: IgG

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for SLAMF6

Target: SLAMF6 (SLAM Family Member 6 (SLAMF6))

Alternative Name: SLAMF6 (SLAMF6 Products)

Synonyms: SLAMF6 antibody, CD352 antibody, KALI antibody, KALIb antibody, Ly108 antibody, NTB-A antibody, NTBA antibody, SF2000 antibody, KAL1 antibody, KAL1b antibody, RGD1561848 antibody, SLAM family member 6 antibody, SLAMF6 antibody, Slamf6 antibody

Background:

Background: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Triggers cytolytic activity only in natural killer cells (NK) expressing high surface densities of natural cytotoxicity receptors (PubMed:11489943, PubMed:16920955). Positive signaling in NK cells implicates phosphorylation of VAV1. NK cell activation seems to depend on SH2D1B and not on SH2D1A (PubMed:16920955). In conjunction with SLAMF1 controls the transition between positive selection and the subsequent expansion and differentiation of the thymocytic natural killer T (NKT) cell lineage (By similarity). Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion, the costimulatory activity requires SH2D1A (PubMed:22184727, PubMed:16920955). Promotes recruitment of RORC to the IL-17 promoter (PubMed:22989874). In conjunction with SLAMF1 and CD84/SLAMF5 may be a negative regulator of the humoral immune response. In the absence of SH2D1A/SAP can transmit negative signals to CD4(+) T-cells and NKT cells. Negatively regulates germinal center formation by inhibiting T-cell:B-cell adhesion, the function probably implicates increased association with PTPN6/SHP-1 via ITSMs in absence of SH2D1A/SAP. However, reported to be involved in maintaining B-cell tolerance in germinal centers and in preventing autoimmunity (By similarity).

Aliases: Activating NK receptor antibody, CD352 antibody, KALI antibody, KALIb antibody, LY108 antibody, MGC104953 antibody, Natural killer T and B cell antigen antibody, NK T B antigen antibody, NK-, T-, and B-cell antigen antibody, NK-T-B-antigen antibody, NTB A antibody, NTB-A antibody, NTBA antibody, NTBA receptor antibody, SF2000 antibody, SLAF6_HUMAN antibody, SLAM family member 6 antibody, SLAM family member 6 precursor antibody, SLAM Family Receptor antibody, Slamf6 antibody

UniProt: Q96DU3